Efavirenz overdosage

Jump to navigation Jump to search
Efavirenz
SUSTIVA® FDA Package Insert
Description
Clinical Pharmacology
Microbiology
Indications and Usage
Contraindications
Warnings and Precautions
Adverse Reactions
Overdosage
Clinical Studies
Dosage and Administration
How Supplied
Labels and Packages

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Ahmed Zaghw, M.D. [2]

Overdosage

Some patients accidentally taking 600 mg twice daily have reported increased nervous system symptoms. One patient experienced involuntary muscle contractions.

Treatment of overdose with SUSTIVA should consist of general supportive measures, including monitoring of vital signs and observation of the patient’s clinical status. Administration of activated charcoal may be used to aid removal of unabsorbed drug. There is no specific antidote for overdose with SUSTIVA. Since efavirenz is highly protein bound, dialysis is unlikely to significantly remove the drug from blood.[1]

References

  1. "SUSTIVA (EFAVIRENZ) CAPSULE, GELATIN COATED SUSTIVA (EFAVIRENZ) CAPSULE, GELATIN COATED SUSTIVA (EFAVIRENZ) TABLET, FILM COATED [BRISTOL-MYERS SQUIBB PHARMA COMPANY]".

Adapted from the FDA Package Insert.